These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 9840689)

  • 21. Incidence and economic implications of heparin-induced thrombocytopenia in medical patients receiving prophylaxis for venous thromboembolism.
    Creekmore FM; Oderda GM; Pendleton RC; Brixner DI
    Pharmacotherapy; 2006 Oct; 26(10):1438-45. PubMed ID: 16999654
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Prevention of venous thromboembolism in internal medicine and neurology].
    Malý J; Dulícek P; Penka M; Malý R; Gumulec J
    Vnitr Lek; 2006 Mar; 52 Suppl 1():63-7. PubMed ID: 16637452
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The role of low molecular weight heparin in total knee arthroplasty.
    Iobst CA; Friedman RJ
    Am J Knee Surg; 1999; 12(1):55-60. PubMed ID: 10050695
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Venous thromboembolism following total knee replacement.
    Choi BY; Huo MH
    J Surg Orthop Adv; 2007; 16(1):31-5. PubMed ID: 17371645
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of six-month outcome of patients initially treated for acute deep vein thrombosis with a low molecular weight heparin Certoparin at a fixed, body-weight-independent dosage or unfractionated heparin.
    Harenberg J; Riess H; Büller HR; Brom J; Weidinger G; Huisman MV
    Haematologica; 2003 Oct; 88(10):1157-62. PubMed ID: 14555312
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The use of antithrombotic drugs in older people.
    Tufano A; Cerbone AM; Di Minno G
    Minerva Med; 2002 Feb; 93(1):13-26. PubMed ID: 11850611
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Low-molecular-weight heparin in cancer-associated thrombosis: treatment, secondary prevention, and survival.
    Nishioka J; Goodin S
    J Oncol Pharm Pract; 2007 Jun; 13(2):85-97. PubMed ID: 17873108
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Update of the management of venous thromboembolism.
    Rodrigues HL; Brandão ES; Lima BS
    Rev Port Cardiol; 2002 Feb; 21(2):183-99. PubMed ID: 11963288
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Expedited discharge in trauma patients requiring anticoagulation for deep venous thrombosis prophylaxis: the LEAP Program.
    Bridges GG; Lee MD; Jenkins JK; Stephens MA; Croce MA; Fabian TC
    J Trauma; 2003 Feb; 54(2):232-5. PubMed ID: 12579045
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Heparins and venous thromboembolism: current practice and future directions.
    Prandoni P
    Thromb Haemost; 2001 Jul; 86(1):488-98. PubMed ID: 11487039
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Prophylaxis of recurrence during transient risk in patients with previous venous thromboembolism].
    Schmidt B; Schellong S
    Med Klin (Munich); 2003 Aug; 98(8):447-52. PubMed ID: 12928810
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Current management of acute symptomatic deep vein thrombosis.
    Heit JA
    Am J Cardiovasc Drugs; 2001; 1(1):45-50. PubMed ID: 14728051
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The therapeutic range for heparin therapy: relationship between six activated partial thromboplastin time reagents and two heparin assays.
    Kitchen S; Preston FE
    Thromb Haemost; 1996 May; 75(5):734-9. PubMed ID: 8725715
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Anticoagulation in Patients With Cirrhosis: Caught Between a Rock-Liver and a Hard Place.
    Ha NB; Regal RE
    Ann Pharmacother; 2016 May; 50(5):402-9. PubMed ID: 26861989
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical evaluation of new global clotting assay for monitoring of LMWH treatment: pilot study.
    Makris PE; Pithara E
    Int Angiol; 1998 Jun; 17(2):69-79. PubMed ID: 9754892
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Inability of the activated partial thromboplastin time to predict heparin levels. Time to reassess guidelines for heparin assays.
    Baker BA; Adelman MD; Smith PA; Osborn JC
    Arch Intern Med; 1997 Nov; 157(21):2475-9. PubMed ID: 9385299
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Subcutaneous unfractionated heparin compared with low-molecular-weight heparin for the initial treatment of venous thromboembolism.
    Bernardi E; Prandoni P
    Curr Opin Pulm Med; 2005 Sep; 11(5):363-7. PubMed ID: 16093806
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Heparin monitoring in acute thrombosis associated with antiphospholipid antibody syndrome.
    Wittkowsky AK; Kino KJ
    Pharmacotherapy; 1995; 15(4):517-21. PubMed ID: 7479207
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Prevention of venous thromboembolism: generally accepted guidelines].
    Gumulec J; Penka M; Bezdĕk R; Wróbel M; Kessler P; Brejcha M; Klodová D; Sumná E; Králová S
    Vnitr Lek; 2006 Mar; 52 Suppl 1():6-16. PubMed ID: 16637444
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prevention of venous thromboembolism.
    Agnelli G; Sonaglia F
    Thromb Res; 2000 Jan; 97(1):V49-62. PubMed ID: 10668808
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.